The story has been updated to include comments from NeoGenomics' conference call on Tuesday. 

NEW YORK (GenomeWeb) – NeoGenomics today reported a 5 percent year-over-year rise in revenues for the second quarter, driven by strong growth in clinical genetic testing.

For the three months ended June 30, the Fort Myers, Florida-based cancer genetic testing firm recorded $66.1 million in total revenues, up from $63.1 million in the year-ago period and beating the consensus Wall Street estimate of $63.0 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.